

PI Major Mutations:None

PI Accessory Mutations:None

PR Other Mutations:I13V <sup>100%</sup><sub>cons=1,202</sub> • I15V <sup>100%</sup><sub>cons=2,214</sub> <sup>100%</sup><sub>cons=1,421%</sub> • E35D <sup>100%</sup><sub>cons=2,212</sub> • N37S <sup>100%</sup><sub>cons=2,21%</sub> • R41K <sup>100%</sup><sub>cons=4,226%</sub> • R57RK <sup>100%</sup><sub>cons=4,229%</sub> <sup>100%</sup><sub>cons=1,527%</sub> <sup>100%</sup><sub>cons=1,421%</sub> • L63LP <sup>100%</sup><sub>cons=2,205%</sub> • K64V <sup>70%</sup><sub>cons=3,301%</sub>

Protease Inhibitors	
atazanavir/r (ATV/r)	Susceptible
darunavir/r (DRV/r)	Susceptible
fosamprenavir/r (FPV/r)	Susceptible
indinavir/r (IDV/r)	Susceptible
lopinavir/r (LPV/r)	Susceptible
nelfinavir (NFV)	Susceptible
saquinavir/r (SQV/r)	Susceptible
tipranavir/r (TPV/r)	Susceptible

No drug resistance mutations were found for PI.

NRTI Mutations:None

NNRTI Mutations:[K103N](#) <sup>100%</sup><sub>cons=1,206%</sub>

RT Other Mutations:V35T <sup>100%</sup><sub>cons=1,242</sub> • E40ED <sup>100%</sup><sub>cons=1,230</sub> <sup>100%</sup><sub>cons=1,421%</sub> • K49R <sup>100%</sup><sub>cons=1,242</sub> • V60I <sup>100%</sup><sub>cons=1,229%</sub> • V90I <sup>100%</sup><sub>cons=1,236%</sub> <sup>100%</sup><sub>cons=1,421%</sub> • D177EG <sup>100%</sup><sub>cons=2,221%</sub> <sup>100%</sup><sub>cons=1,547%</sub> <sup>100%</sup><sub>cons=1,421%</sub> • V179I <sup>100%</sup><sub>cons=2,287</sub> <sup>100%</sup><sub>cons=1,547%</sub> <sup>100%</sup><sub>cons=1,301%</sub> • G196E <sup>100%</sup><sub>cons=2,214</sub> • T200I <sup>100%</sup><sub>cons=2,201%</sub> • Q207GR <sup>100%</sup><sub>cons=2,289%</sub> <sup>100%</sup><sub>cons=1,421%</sub> <sup>100%</sup><sub>cons=1,301%</sub> • R211K <sup>100%</sup><sub>cons=1,271</sub> • V245K <sup>100%</sup><sub>cons=2,282</sub> • D250E <sup>100%</sup><sub>cons=1,628%</sub> • K530R <sup>100%</sup><sub>cons=4,23%</sub> • A534S <sup>100%</sup><sub>cons=2,282</sub> • V548I <sup>100%</sup><sub>cons=1,217</sub> • A554N <sup>100%</sup><sub>cons=2,21%</sub>

Nucleoside Reverse Transcriptase Inhibitors		Non-nucleoside Reverse Transcriptase Inhibitors	
abacavir (ABC)	Susceptible	doravirine (DOR)	Susceptible
zidovudine (AZT)	Susceptible	efavirenz (EFV)	High-Level Resistance
stavudine (D4T)	Susceptible	etravirine (ETR)	Susceptible
didanosine (DDI)	Susceptible	nevirapine (NVP)	High-Level Resistance
emtricitabine (FTC)	Susceptible	rilpivirine (RPV)	Susceptible
lamivudine (3TC)	Susceptible		
tenofovir (TDF)	Susceptible		

RT comments

NNRTI

- K103N** is a non-polymorphic mutation that confers high-level reductions in NVP and EFV susceptibility. It is the most commonly transmitted DRM.

Other

- V90I** is a polymorphic accessory mutation weakly selected by each of the NNRTIs. It is associated with minimal, if any, detectable reduction in NNRTI susceptibility.
- V179I** is a polymorphic mutation that is frequently selected in persons receiving ETR and RPV. However, it has little, if any, direct effect on NNRTI susceptibility.

No drug resistance mutations were found for NRTI.

Drug resistance mutation scores of NNRTI:

Download CSV

Rule	DOR <sup>±</sup>	EFV <sup>±</sup>	ETR <sup>±</sup>	NVP <sup>±</sup>	RPV <sup>±</sup>
<a href="#">K103N</a>	0	60	0	60	0

INSTI Major Mutations:None

INSTI Accessory Mutations:None

IN Other Mutations:E10D <sup>100%</sup><sub>cons=2,229%</sub> • K14KR <sup>100%</sup><sub>cons=4,221%</sub> <sup>100%</sup><sub>cons=1,421%</sub> • K34KR <sup>100%</sup><sub>cons=2,282%</sub> • M50L <sup>100%</sup><sub>cons=4,22%</sub> • I72V <sup>100%</sup><sub>cons=2,21%</sub> • L101L <sup>100%</sup><sub>cons=4,22%</sub> <sup>100%</sup><sub>cons=1,21%</sub> <sup>100%</sup><sub>cons=1,201%</sub> • T112V <sup>100%</sup><sub>cons=4,217</sub> • I113V <sup>100%</sup><sub>cons=4,217</sub> • T124A <sup>100%</sup><sub>cons=1,287</sub> • T125A <sup>100%</sup><sub>cons=2,287</sub> • V201I <sup>100%</sup><sub>cons=4,222%</sub> • L234I <sup>100%</sup><sub>cons=1,21%</sub> • A265V <sup>70%</sup><sub>cons=3,301%</sub>

Integrase Strand Transfer Inhibitors	
bictegravir (BIC)	Susceptible
cabotegravir (CAB)	Susceptible
dolutegravir (DTG)	Susceptible
elvitegravir (EVG)	Susceptible
raltegravir (RAL)	Susceptible

No drug resistance mutations were found for INSTI.